The compiled data demonstrates impressively, that dronabinol should be considered in selected cases of patients with acute leukemia but also stresses on the importance of thoroughly reflecting on the individual expression profiles of CB1/CB2 as well as on additional diagnostic criteria—as e.g. lymphatic markers. The gene discussed is CNR1; the disease is acute leukemia.